Suramin increases p53 protein levels but does not activate the p53-dependent G1 checkpoint

Clinical Cancer Research

Volumn 2, Issue 2, 1996, Pages 269-276

  Howard, Steven P ^a,b   Park, Sonia J ^a   Hughes Davies, Luke ^a   Coleman, C Norman ^a   Price, Brendan D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; SURAMIN;

ANIMAL CELL; ARTICLE; CELL CYCLE G1 PHASE; CELL STRAIN 3T3; CONTROLLED STUDY; GROWTH INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA DAMAGE; G1 PHASE; MICE; RNA, MESSENGER; SURAMIN; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029991322     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Stein, C. A. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res., 53: 2239-2248, 1993.
2. Myers, C., Cooper, M., Stein, C , LaRocca, R., Walther, M., Weiss, G , Choyke, P., Dawson, N., Steinberg, S., Ehrich, M., Cassidy, J., Kohler, K., Trepel, J., and Linehem, W. Suramin: a novel growth factor antagonist with activity in hormone refractory metastatic prostate cancer. J. Clin. Oncol., 10: 881-889, 1992.
3. Sklar, G. N., Eddy, H. A., Jacobs, S. C., and Kypnrianou, N. Combined effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis. J. Urol., 150: 1526-1532, 1993.
4. Peehl, D. M., Wong, S. T., and Stamey, T. A. Cytostatic effects of suramin on prostate cancer cells cultured from primary tumors. J. Urol., 145: 624-630, 1991.
5. Vignon, F., Prebois, C , and Rochefort, H. Inhibition of breast cancer growth by suramin. J. Natl. Cancer Inst., 84: 38-42, 1991.
6. Kraft, A., Reid, L. M., and Zvibel, I. Suramin inhibits growth and yet promotes insulin-like growth factor II expression in HepG2 cells. Cancer Res., 53: 652-657, 1993.
7. Betsholtz, C., Johnson, A., Heldin, C-H., and Westermark, B. Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin. Proc. Natl. Acad. Sci. USA, 83: 6440-6444, 1986.
8. Hosang, M. Suramin binds to platelet-derived growth factor and inhibits biological activity. J. Cell. Biochem., 29: 265-273, 1985.
9. Pollak, M., and Richard, M. Suramin blockade of insulin-like growth factor 1-stimulated proliferation of human osteosarcoma cells. J. Natl. Cancer Inst., 82: 1349-1352, 1990.
10. Jindal, H. K., Anderson, C. W., Davis, R. G., and Vishwanatha, J. K. Suramin affects DNA synthesis in HeLa Cells by inhibition of DNA polymerases. Cancer Res., 50: 7754-7757, 1990.
11. Rago, R., Mitchen, J., Cheng, A-L., Oberley, T., and Wilding, G. Disruption of the cellular energy balance by suramin in intact human prostatic carcinoma cells, a likely antiproliferative mechanism. Cancer Res , 51: 6629-6635, 1991.
12. Hensey, C , Boscoboinik, D., and Azzi, A. Suramin, an anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A. FEBS Lett., 258: 156-158, 1989.
13. Mahoney, C., Azzi, A., and Huang, K. Effects of suramin, an anti-immunodeficiency virus reverse transcriptase agent, on protein kinase C. J. Biol. Chem., 265: 5424-5428, 1990.
14. Kopp, R., and Pfeiffer, A. Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cells. Cancer Res., 50: 6490-6496, 1990.
15. 2+ concentration Cancer Lett., 49: 107-113, 1989.
16. Bojanowski, K., LeLievre, S., Morkovits, J., Couprie, J., Jacquemin-Sablon, A., and Larsen, A. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc. Natl. Acad. Sci. USA, 89: 3025-3029, 1992.
17. Howard, S. P., Groch, K. M , Lindstrom, M. J., Messing, E. M., and Gould, M. N. Proliferation-independent growth factor modulation of radiation sensitivity of human prostate cells. Radiat. Res., 143: 229-233, 1995.
18. Weinert, T. A., and Hartwell, L H. The rad9 gene controls the cell cycle response to DNA damage in saccharomyces cerevisiae. Science (Washington DC), 241: 317-322, 1988.
19. Lau, C. C., and Pardee, A. B. Mechanism by which caffeine potentiates lethality of nitrogen mustard Proc. Natl Acad. Sci. USA, 79: 2942-2946, 1982
20. Tolmach, L. J , Jones, R W., and Busse, P. M. The action of caffeine on X-ray irradiated HeLa cells: delayed inhibition of DNA synthesis. Radiat. Res., 71: 653-665, 1977.
21. Lane, D. P p53, guardian of the genome. Nature (Lond), 358: 80-83, 1992.
22. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991
23. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
24. Kastan, M. B , Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Watsh, W , Plunkett, B. S., Vogelstein, B., and Fornace, A. J. A mammalian cell cycle checkpoint utilizing p53 and gadd45 is defective in ataxia telangiectasia. Cell, 71: 587-597, 1992.
25. Tishler, R. B., Calderwood, S. K., Coleman, C. N , and Price, B. D. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res., 53: 2212-2216, 1993.
26. Price, B. D., and Calderwood, S. K. Increased sequence-specific p53-DNA binding activity after DNA damage is attenuated by phorbol esters. Oncogene, 8: 3055-3062, 1993.
27. Funk, W. D., Pak, D. T., Karas, R. H., Wright, W. E., and Shay, J. W. A Transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol., 12: 2866-2871, 1992.
28. Baker, S. J., Markovitz, S., Fearon, E. R., Wilson, J. K. V., and Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (Washington DC), 249: 912-915, 1990.
29. Gratzner, H., Monoclonal antibody to 5 bromo- and 5-iododeoxyuridine. A new reagent for detection of DNA replication. Science (Washington DC), 218: 474-475, 1982.
30. 1 cyclin-dependent kinase. Cell, 75: 805-816, 1993.
31. Price, B. D., Hughes-Davies, L., and Park, S. J. Cdk2 kinase phosphorylates serine 315 of human p53 in vitro. Oncogene, 11: 73-80, 1995.
32. Chirgwin, J. A., Pryzbyla, R., McDonald, R., and Rotter, W. Isolation of biologically active ribonucleic acid from sources rich in ribonuclease. Biochemistry. 18: 5294-5295, 1979.
33. 2+ is essential for multistep activation of the heat shock factor in permeabilized cells. Mol. Cell. Biol., 6: 3365-3368, 1991.
34. El-Deiry, W. S., Tokino, T., Velcelescu, V. E., Levy, D B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
35. 1 arrest. Cell, 76: 1013-1023, 1994.
36. 1 cyclins. Cell, 73: 1059-1063, 1993.
37. Nelson, W. G., and Kastan, M. B. DNA strand breaks: the DNA template alterations that trigger p53 dependent DNA damage response pathways. Mol. Cell. Biol., 14: 1815-1823, 1994.
38. Reich, N. C., and Levine, A. J Growth regulation of a cellular tumor antigen, p53, in non-transformed cells. Nature (Lond.), 308: 199-201, 1984.
39. Berns, E. M., Schuurmans, A. L., Bolt, J., Lamb, D J., Foekens, J. A., and Mulder, E. Antiproliferative effects of suramin on androgen responsive tumor cells. Eur. J. Cancer, 26: 470-474, 1990.
40. Qiao L., Pizzolo, J. G , and Melamed, M. R. Effects of suramin on expression of proliferation associated nuclear antigens in DU-145 prostate carcinoma cells. Biochem. Biophys. Res. Commun., 201: 581-588, 1994.
41. Foekens, J. A., Sieuwerts, A. M., Stuurman-Smeets, E. M. J, Peters, H. A., and Klijn, J. G. M. Effects of suramin on cell-cycle kinetics of MCF-7 human breast cancer cells in vitro. Br. J. Cancer, 67: 232-236, 1993.
42. Ewing, M. W., Liu, S. C., Gnarra, J. R. Walther, M. M., Meyers, C. E., and Linehan, W. M. Effect of suramin on the mitogenic response of the human prostate carcinoma cell line PC-3. Cancer (Phila.), 71: 1151-1158, 1993.
43. 1 cyclin-Cdk protein kinase activity, is related to p21. Cell, 78: 67-74, 1994.
44. Polyak, K., Lee, M. H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., and Massague. J. Cloning of p27 Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 67-74, 1994.
45. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704-707, 1993.
46. Hannon, G. J., and Beach, D. p15 INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature (Lond.), 371: 257-261, 1994.
47. Hirai, H., Roussel, M. F., Kato, J. Y., Ashmun, R. A. and Sherr, C. J. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell. Biol., 15: 672-681, 1995.
48. Chan, F. K., Zhang, J., Cheng, L., Shapiro, D. N., and Winoto, A. Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16 INK4. Mol. Cell. Biol., 15: 2682-2688, 1995
49. Lowe, S. W., Schimtt, S. W., Smith, S. W., Osborne, B. A., and Jacks, T. p53 function is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 847-849, 1993.
50. Kinsella, T. J., Gould, M. N., Mulcahy, R. T., Ritter, M. A., and Fowler, J. F. Keynote Address: Integration of cytostatic agents and radiation therapy: A different approach to "proliferating" human tumors. Int. J. Oncol. Biol. Phys., 20: 295-302, 1991.
51. Lowe, S. W., Ruley, H. W., Jacks, T., and Housman, D. E. p53-dependent apotosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993
52. Lowe, S. W., Bodis, S., McCarthy A., Remington, L., Ruley, H W., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC). 266: 807-810, 1994.
53. Khaled, Z., Rideout, D., O'Driscoll, K. R., Petralyk, D., Cacace, A., Patel, R., Chiang, L-C., Rotenberg, S., and Stein, C. A. Effects of suramin related and other clinically therapeutic polyanions on protein kinase C activity. Clin. Cancer Res., 1: 113-122, 1995.
54. Bischoff, J. R , Friedman, P. N., Marshak, D. R., Prives, C. and Lee, W-H. Genetic mechanisms of tumor suppression by the p53 gene. Science (Washington DC), 250: 1576-1580, 1990.
55. 2 stimulate mitogen activated protein kinase activity in NIH-3T3 cells through the formation of reactive oxygen intermediates. Cancer Res., 54: 12-15, 1994.
56. Lees-Miller, S. P., Chen, Y-R., and Anderson, C. W. Human cells contain a DNA activated protein kinase that phosphorylates simian virus 40 T antigen, mouse p53 and the human Ku antigen. Mol. Cell. Biol., 10: 6472-6481, 1990.